Related Experiment Video
Updated: Dec 9, 2025
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
14.9K
Emerging Pharmacotherapy to Reduce Elevated Lipoprotein(a) Plasma Levels
Nathaniel Eraikhuemen1, Dovena Lazaridis2, Matthew T Dutton3
1College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health, Florida A&M University, Davie, FL, 33324, USA.
Summary
Elevated Lipoprotein(a) levels increase the risk of premature cardiovascular disease. Emerging therapies show promise for managing high Lipoprotein(a) where statins fail.
Area of Science:
- Cardiovascular Medicine
- Lipid Metabolism
- Atherosclerosis Research
Background:
- Lipoprotein(a) [Lp(a)] is a modified low-density lipoprotein linked to premature atherosclerotic diseases.
- High Lp(a) levels correlate with increased incidence of coronary artery disease, myocardial infarction, and stroke.
- Lp(a) plasma levels and activity vary significantly due to apolipoprotein A kringle repeat variability.
Purpose of the Study:
- To review the role of Lipoprotein(a) in atherogenesis.
- To discuss the limitations of current therapies for elevated Lp(a).
- To highlight emerging pharmacologic strategies for managing high Lp(a) levels.
Main Methods:
- Literature review of Lipoprotein(a) function and clinical impact.
- Analysis of current and novel lipid-lowering therapies.
- Synthesis of evidence on Lp(a)-associated cardiovascular risk.
Main Results:
- Lipoprotein(a) is present in arterial walls and contributes to foam cell formation and lipid deposition in atherosclerotic plaques.
- Conventional lipid-lowering drugs like statins are ineffective at reducing Lp(a) levels.
- Novel agents, including PCSK9 inhibitors and antisense oligonucleotides, demonstrate potential for Lp(a) management.
Conclusions:
- Lipoprotein(a) is a significant, independent risk factor for premature cardiovascular events.
- Effective pharmacologic management of elevated Lp(a) requires novel therapeutic approaches beyond traditional lipid-lowering agents.
- Emerging therapies offer new hope for reducing cardiovascular risk in individuals with high Lp(a).
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.2K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.2K
01:26Atherosclerosis III: Management
225
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
225
01:26Coronary Artery Disease IV: Preventive Measures
507
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
507
01:27Bioavailability Enhancement: Drug Permeability Enhancement
107
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
107
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
475
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
475
01:27Peripheral Artery Disease III: Interprofessional Care
156
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
156